Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(7)
•••
Comment by Staghorn69on Dec 18, 2017 11:12am
167 Views
Post# 27178510

RE:RE:PG, 4050 and IPF

RE:RE:PG, 4050 and IPF
Dibah42 wrote:
stockman6767 wrote: Does this morning's PR about orphan status for  PG to treat IPF mean that they are now looking at a twp prong attack on IPF using both PG AND 4050 to treat IPF? This sounds new to me. Have any of you had an inkling of this new approach?



Ryplazim for IPF is news to me.  I wasn't aware of any ongoing clinical studies.  Unusual to see them go from animal model straight to ODS.
Cheers



Ok so I’m not crazy...  interesting development.  I think we should see a 4050 / Ryplazim two prong study arm in the upcoming IPF trials....  talk about covering the bases.  
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities